Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline
01:15am, Wednesday, 24'th Dec 2025
Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline Paris, December 24, 2025. Sanofi announced today that it has entered into an agr
Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
01:00am, Wednesday, 24'th Dec 2025
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Paris, December 24, 2025. The US Food and Drug Administration (FDA) has issued a
Press Release: Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia
09:06am, Tuesday, 23'rd Dec 2025
Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ITP
Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
01:00am, Tuesday, 23'rd Dec 2025
Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduce
Sanofi: Information concerning the total number of voting rights and shares - November 2025
12:35pm, Monday, 22'nd Dec 2025
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement
Osaic Holdings Inc. Raises Stock Holdings in Sanofi $SNY
05:20am, Sunday, 21'st Dec 2025
Osaic Holdings Inc. boosted its holdings in Sanofi (NASDAQ: SNY) by 17.0% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commissi
Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal
01:38am, Saturday, 20'th Dec 2025
Trump and nine major pharmaceutical companies struck deals to lower drug prices for cash payers and Medicaid, with over $150 billion pledged for U.S. R&D and manufacturing.
Market Today: Oracle-TikTok JV, Tesla Pay Reinstated, Nike Sinks
05:35pm, Friday, 19'th Dec 2025
Guru Stock PicksVanguard Health Care Fund has made the following transactions:Reduce in ARGX by 14.38%Sold out in PACSAdd in CLDX by 3.64%New position in PTGXCI
Trump strikes deal with US drugmakers to cut Medicaid medicine costs
03:14pm, Friday, 19'th Dec 2025
Officials pledge ‘massive savings' as companies agree to offer drugs at prices paid in other wealthy countries
Nine of the largest pharma companies ink deals with Trump to lower drug prices
02:34pm, Friday, 19'th Dec 2025
Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation's drug
Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation
02:21pm, Friday, 19'th Dec 2025
Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation Agreement delivers on President Trump's four requests, establishing a framework for lower prices
SNY's Rare Disease Drug Efdoralprin Alfa Gets EMA's Orphan Drug Tag
11:56am, Thursday, 18'th Dec 2025
Sanofi gains EMA Orphan Drug status for efdoralprin alfa, a phase II biologic for AATD-related emphysema with promising dosing data.
Sanofi (SAN:CA) Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments Transcript
09:59pm, Tuesday, 16'th Dec 2025
Sanofi (SAN:CA) Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments Transcript
SNY Stock Down on Double Trouble With Multiple Sclerosis Drug
11:46am, Tuesday, 16'th Dec 2025
Sanofi shares slide after the FDA again delays its review of its MS drug tolebrutinib, and a phase III study fails to hit its primary endpoint.
South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi
06:57pm, Monday, 15'th Dec 2025
South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi to develop and sell the biotech company's experimental Alzheimer's disease treat
